In a ground-breaking study, a team of doctors from HCG Cancer Hospital, Bengaluru led by Dr. Gururaj Arakeri Dr. Vishal Rao US, Dr Shekhar Patil and team has discovered a potential new cause for Oral Submucous Fibrosis (OSMF), a pre-cancerous condition that results in the
Semaglutide, a GLP-1 receptor analogue (GLP-1 RA), indicated for the management of type 2 diabetes has been developed in an oral formulation for the first time. Oral semaglutide will be a gamechanger for people with type 2 diabetes who prefer oral medications over injections. was
